在惩教环境中管理和治疗丙型肝炎的新机遇。
New opportunities for the management and therapy of hepatitis C in correctional settings.
机构信息
Medcenter One Health Systems, 222 N 7th St, Bismark, ND 58501, USA.
出版信息
Am J Public Health. 2010 Jan;100(1):13-7. doi: 10.2105/AJPH.2008.147629.
Abstract
Hepatitis C in prison populations is now a major public health problem, and large numbers of correctional facilities have no comprehensive management program, often because of formidable projected costs and tightening budget constraints. The North Dakota Department of Corrections and Rehabilitation has operated a management and therapy program since 2002 using consensus interferon and ribavirin with 45% cost savings. The program has provided excellent sustained viral responses: 54.2% for genotype 1 hepatitis C, 75% for genotypes 2 and 3, and 63.6% overall.
摘要
监狱人群中的丙型肝炎现在是一个主要的公共卫生问题，许多惩教设施没有全面的管理方案，这往往是因为预计费用巨大和预算紧张。北达科他州惩教和康复部自 2002 年以来一直使用共识干扰素和利巴韦林实施管理和治疗方案，节省了 45%的成本。该方案提供了极好的持续病毒应答率：基因型 1 丙型肝炎为 54.2%，基因型 2 和 3 为 75%，总体为 63.6%。
相似文献
1
New opportunities for the management and therapy of hepatitis C in correctional settings.在惩教环境中管理和治疗丙型肝炎的新机遇。
Am J Public Health. 2010 Jan;100(1):13-7. doi: 10.2105/AJPH.2008.147629.
2
A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.新型丙型肝炎治疗药物的预算影响分析及州惩教系统的财务负担
J Urban Health. 2015 Aug;92(4):635-49. doi: 10.1007/s11524-015-9953-4.
3
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.评估监狱和社区环境中感染 HIV 的患者使用聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎和直接作用抗病毒药物的成本效益。
J Microbiol Immunol Infect. 2019 Aug;52(4):556-562. doi: 10.1016/j.jmii.2018.10.002. Epub 2018 Oct 12.
4
5
Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
Am J Health Syst Pharm. 2004 Jul 15;61(14):1479-82. doi: 10.1093/ajhp/61.14.1479.
6
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.多学科支持方案提高聚乙二醇干扰素 α-2a 和利巴韦林治疗丙型肝炎的疗效。
J Hepatol. 2013 Nov;59(5):926-33. doi: 10.1016/j.jhep.2013.06.019. Epub 2013 Jun 26.
7
ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE.塞尔维亚监狱环境中丙型肝炎的抗病毒治疗：医疗治疗结果与患者依从性
Med Pregl. 2016 Mar-Apr;69(3-4):85-91. doi: 10.2298/mpns1604085s.
8
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.聚乙二醇化干扰素α-2a和α-2b联合利巴韦林治疗慢性丙型肝炎：系统评价与经济学评估
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
9
Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.人格障碍不影响西班牙囚犯慢性丙型肝炎病毒感染的治疗结果：珀尔修斯研究。
BMC Infect Dis. 2015 Aug 19;15:355. doi: 10.1186/s12879-015-1102-x.
10
Combination therapy for hepatitis C infection.丙型肝炎感染的联合治疗。
N Engl J Med. 1999 Apr 15;340(15):1207; author reply 1208-9.
引用本文的文献
1
Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment.丙型肝炎病毒感染与囚犯：流行病学、转归及治疗
World J Hepatol. 2015 Sep 28;7(21):2323-30. doi: 10.4254/wjh.v7.i21.2323.
2
A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.新型丙型肝炎治疗药物的预算影响分析及州惩教系统的财务负担
J Urban Health. 2015 Aug;92(4):635-49. doi: 10.1007/s11524-015-9953-4.
3
"Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.美国刑事司法系统中丙型肝炎的“筛查、检测、治疗与留存”
Int J Prison Health. 2014;10(3):164-71. doi: 10.1108/IJPH-11-2013-0051.
4
Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study.缺乏医疗保险限制了丙型肝炎病毒筛查的益处：来自美国国家健康与营养检查丙型肝炎随访研究的见解。
Am J Gastroenterol. 2015 Aug;110(8):1126-33. doi: 10.1038/ajg.2015.31. Epub 2015 Mar 10.
5
Survey of US Correctional Institutions for Routine HCV Testing.美国惩教机构常规丙型肝炎病毒检测调查。
Am J Public Health. 2015 Jan;105(1):68-71. doi: 10.2105/AJPH.2014.302071.
6
Hepatitis C in European prisons: a call for an evidence-informed response.欧洲监狱中的丙型肝炎：呼吁基于证据的应对措施。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S17. doi: 10.1186/1471-2334-14-S6-S17. Epub 2014 Sep 19.
7
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.丙型肝炎管理的最新进展：加拿大肝脏研究协会的共识指南
Can J Gastroenterol. 2012 Jun;26(6):359-75. doi: 10.1155/2012/947676.
8
Public health and the epidemic of incarceration.公共卫生与监禁潮。
Annu Rev Public Health. 2012 Apr;33:325-39. doi: 10.1146/annurev-publhealth-031811-124614. Epub 2012 Jan 3.
本文引用的文献
1
The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.共识干扰素在当前慢性丙型肝炎病毒感染治疗中的作用。
Gastroenterol Hepatol (N Y). 2008 Sep;4(9 18):1-12.
2
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.聚乙二醇干扰素α-2b或α-2a联合利巴韦林用于治疗丙型肝炎感染。
N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22.
3
Treating hepatitis C in the prison population is cost-saving.在监狱人群中治疗丙型肝炎可节省成本。
Hepatology. 2008 Nov;48(5):1387-95. doi: 10.1002/hep.22509.
4
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations.监狱环境中丙型肝炎治疗的临床结果：对具有挑战性的治疗人群的可行性和有效性
Clin Infect Dis. 2008 Oct 1;47(7):952-61. doi: 10.1086/591707.
5
Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C.聚乙二醇干扰素 alfa-2a：一种新型干扰素，用于治疗慢性丙型肝炎。
BioDrugs. 1999 Nov;12(5):343-57. doi: 10.2165/00063030-199912050-00003.
6
Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.丙型肝炎病毒1型对普通干扰素和利巴韦林与聚乙二醇化干扰素和利巴韦林的抗病毒反应。
Dig Dis Sci. 2007 Jun;52(6):1540-7. doi: 10.1007/s10620-007-9757-9. Epub 2007 Apr 4.
7
Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.慢性丙型肝炎抗病毒治疗诱导的精神症状：α-干扰素-2a与α-干扰素-2b的比较
Clin Drug Investig. 2006;26(11):655-62. doi: 10.2165/00044011-200626110-00005.
8
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.丙型肝炎联合治疗期间发生贫血时血液学生长因子的成本效益
Hepatology. 2006 Dec;44(6):1598-606. doi: 10.1002/hep.21409.
9
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Hepatology. 2006 Dec;44(6):1400-3. doi: 10.1002/hep.21426.
10
HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response.惩教机构囚犯中的艾滋病毒/艾滋病及其他传染病：传播、负担及适当应对措施。
Am J Public Health. 2006 Jun;96(6):974-8. doi: 10.2105/AJPH.2005.066993. Epub 2006 Jan 31.
Zotero 插件